- Home
- INMB vs CTOR Comparison
INMB vs CTOR Comparison
Compare INMB & CTOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INMB
- CTOR
- Stock Information
- Founded
- INMB 2015
- CTOR 2021
- Country
- INMB United States
- CTOR United States
- Employees
- INMB N/A
- CTOR N/A
- Industry
- INMB Biotechnology: Pharmaceutical Preparations
- CTOR
- Sector
- INMB Health Care
- CTOR
- Exchange
- INMB Nasdaq
- CTOR NYSE
- Market Cap
- INMB 68.9M
- CTOR 63.7M
- IPO Year
- INMB 2019
- CTOR N/A
- Fundamental
- Price
- INMB $2.91
- CTOR $1.87
- Analyst Decision
- INMB Buy
- CTOR Buy
- Analyst Count
- INMB 4
- CTOR 2
- Target Price
- INMB $9.53
- CTOR $6.00
- AVG Volume (30 Days)
- INMB 4.5M
- CTOR 2.6M
- Earning Date
- INMB 08-04-2025
- CTOR 08-11-2025
- Dividend Yield
- INMB N/A
- CTOR N/A
- EPS Growth
- INMB N/A
- CTOR N/A
- EPS
- INMB N/A
- CTOR N/A
- Revenue
- INMB $50,000.00
- CTOR N/A
- Revenue This Year
- INMB $203.60
- CTOR N/A
- Revenue Next Year
- INMB $13,122.47
- CTOR N/A
- P/E Ratio
- INMB N/A
- CTOR N/A
- Revenue Growth
- INMB N/A
- CTOR N/A
- 52 Week Low
- INMB $1.89
- CTOR $0.55
- 52 Week High
- INMB $11.64
- CTOR $49.00
- Technical
- Relative Strength Index (RSI)
- INMB 41.06
- CTOR N/A
- Support Level
- INMB $2.62
- CTOR N/A
- Resistance Level
- INMB $3.07
- CTOR N/A
- Average True Range (ATR)
- INMB 0.25
- CTOR 0.00
- MACD
- INMB 0.24
- CTOR 0.00
- Stochastic Oscillator
- INMB 72.26
- CTOR 0.00
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
About CTOR CITIUS ONCOLOGY INC
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.